South San Francisco
|D.E. Shaw group, Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and PAC-LINK|| |
Most of the funding will be used to advance Portola's lead drug betrixaban.
|Light Sciences Oncology |
The funding will be used to advance its work on light infusion therapies.
|Abingworth, Oxford Bioscience Partners and Skyline Ventures|| |
Dicerna Pharmaceuticals is an RNA interference company.
Portola leads with $60M round